김종승 (고려대학교) | 한빛사논문 > 한빛사

한빛사논문

조회121

고려대학교

Proc. Natl. Acad. Sci. USA, Jun 17 2025, 122 (24) | https://doi.org/10.1073/pnas.2503574122 Dual-laser "808 and 1,064 nm" strategy that circumvents the Achilles' heel of photothermal therapy

Qihang Ding ^{1 †}, Jiqiang Liu ^{2 †}, Yue Wang^{2 †}, Jungryun Kim ¹, Zhihui Huang ², Yubin Lee ¹, Hui Zhou ^{3 *}, Pengfei Zhang ^{2 *}, Jonathan L. Sessler ^{4 *}, Jong Seung Kim^{1 *}

¹Department of Chemistry, Korea University, Seoul 02841, Korea.
²Guangdong Key Laboratory of Nanomedicine, Chinese Academy of Sciences-Hong Kong Joint Lab for Biomaterials, Chinese Academy of Sciences Key Laboratory of Biomedical Imaging Science and System, Center for Nanomedicine and Nanobiotechnology, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
³State Key Laboratory of Flexible Electronics & Institute of Advanced Materials, Nanjing University of Posts & Telecommunications, Nanjing 210023, China.
⁴Department of Chemistry, The University of Texas at Austin, Austin, TX 78712-1224.

^†These authors contributed equally

^*Corresponding authors: correspondence to Hui Zhou, Pengfei Zhang, Jonathan L. Sessler or Jong Seung Kim

Abstract

Breast cancer has now overtaken lung cancer as the "world's leading cancer," yet detecting and implementing effective therapies remains a significant challenge. Substantial advances have been made in photothermal therapy (PTT), where photosensitizers use photonic energy to induce localized hyperthermia for cancer eradication. This pioneering approach is gaining traction in clinical settings. However, traditional PTT faces inherent limitations, including the risk of damage to neighboring healthy tissues and potential inflammatory responses due to overheating. Drawing inspiration from the distinct characteristics of aggregation-induced emission the small molecule, PM331, was chosen for study. This donor-acceptor-donor system displays good photothermal conversion efficiencies (40% and 66%) upon excitation at 808 nm and 1,064 nm, respectively. It is also characterized by attractive optical features in the second near-infrared (NIR-II) window. Using nanoparticles containing PM331, PM331@F127, we have developed a PTT strategy, termed dual-laser PTT (DLPTT), that involves successive excitation using 808 nm and 1,064 nm lasers guided by both NIR-II fluorescence and photoacoustic imaging. The DLPTT strategy involves two steps. First, it initiates DNA damage and downregulates heat shock protein expression as the result of an initial brief irradiation with an 808 nm laser. This is then followed by irradiation with a 1,064 nm laser to ablate tumor cells while minimizing inflammation and harm to surrounding healthy tissues. Based on the findings reported here, we suggest that DLPTT could represent an attractive approach to precision medicine and one that could make PTT more amenable to clinical implementation.

논문정보

형식Research article
게재일2025년 06월 (BRIC 등록일 2025-06-10)
연구진국내(교신)+국외 연구진
분야

댓글 작성 로그인

CV 열람하기

연락처 보기